Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Company on track to report topline data in first half of 2025Positive preliminary data from all five single ascending dose (SAD) cohorts ranging ...

(RTTNews) - Palisade Bio, Inc. (PALI), Thursday announced a preliminary data from five planned Single Ascending Dose cohorts, showing that PALI-2018 was well-tolerated among doses ranging from 15 mg ...

Ulcerative colitis during pregnancy is manageable However timely detection and proper treatment are crucial to ensure a ...

THURSDAY, Jan. 16, 2025 (HealthDay News) -- The U.S. Food and Drug Administration ... "With Omvoh approved in both Crohn's ...

Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD), but it can cause body-wide effects that may impair a person’s oral health. Mouth sores, gum disease, and dry mouth are ...

Tulisokibart, a TNF–like cytokine 1A monoclonal antibody, has demonstrated significant potential in inducing clinical ...

New Understanding of the Gut ... disease (IBD), such as Crohn's disease and ulcerative colitis, is on the rise worldwide. The benefits of current medications are limited by problematic side ...

cohorts in its ongoing Phase 1a/b study of PALI-2108 for the treatment of Ulcerative Colitis (UC). Preliminary data from the SAD portion of the study, which evaluated doses ranging from 15 mg to ...